Curia Unveils Comprehensive mRNA Solution
Curia, formerly AMRI, a leading contract research, development and manufacturing organization, today unveiled its messenger RNA (mRNA) solution, which includes discovery, process development and mRNA drug substance production, through large-scale lipid manufacturing, lipid nanoparticle (LNP) formulation and development for full-scale sterile fill-finish services.
Curia’s mRNA solution is designed to streamline the development and delivery of mRNA-based products, which span various therapeutic areas including cancer, heart disease and chronic illnesses in addition to its current application in vaccines.
“The extraordinary impact of mRNA on the COVID-19 pandemic demonstrates its potential to save and improve lives,” said Curia Chairman and Chief Executive Officer John Ratliff. “mRNA has the potential to play a pivotal role in the next frontier of treatments for unmet medical needs. Curia’s capabilities enable customers to accelerate the discovery and development of next-generation mRNA therapeutics from curiosity to cure.”
Curia’s team brings a powerful combination of proven expertise, speed and reliability across research, process development and manufacturing to accelerate mRNA product development timelines:
Discovery
Curia’s mRNA solution combines expertise and a proven track record of success in key scientific disciplines including molecular biology, protein production and analysis, enzymes, nucleosides and lipids. The platform’s ability to provide high-quality constructs through in-house research and analysis capabilities enables accelerated timelines for delivery.
Development of Lipid and RNA Drug Substance Through Manufacturing
Curia’s end-to-end capabilities extend from production of plasmid DNA and manufacturing of enzymes and nucleosides at gram-to-kilogram scale, to drug substance development through first-in-human clinical supply manufacturing. Its five sites in California and Massachusetts provide reliable plasmid production for “traditional” and self-amplifying mRNA drug substance. First-in-human clinical-scale cGMP manufacturing is supplemented by in-house analytical capabilities for product testing and release.
Curia has a proven track record in the rapid development of numerous specialized lipids for mRNA applications and the ability to manufacture lipids to metric-ton scale in accordance with cGMP. Curia’s scientists have expertise in coupling synthesis with highly effective separations and purifications of APIs and functional excipients.
Development of Lipid Nanoparticle Formulation, Testing and Sterile Fill-Finish Through Manufacturing
Curia’s mRNA solution includes complex formulation capabilities and experience in liposome and lipid nanoparticles led by its expert scientists. Curia completes its end-to-end offering with clinical and commercial aseptic sterile fill-finish capability and capacity. Its facilities provide process development and first-in-human clinical manufacturing through to full commercial manufacturing of mRNA injectable dosage products in accordance with cGMP.
About Curia
Curia, formerly AMRI, is a leading contract research, development and manufacturing organization providing products and services from R&D through commercial manufacturing to pharmaceutical and biopharmaceutical customers. Curia’s 3,700 employees at 29 locations across the U.S., Europe and Asia help its customers advance from curiosity to cure. Learn more at CuriaGlobal.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211222005047/en/
Contact information
Corporate Contact:
Sue Zaranek
Curia
+1 518 512 2111
corporatecommunications@CuriaGlobal.com
Media Communications:
Debra Harrsch
Brandwidth Solutions LLC
+1 215 997 8575
dharrsch@bwsmarketing.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT and E.ON Extend Partnership to Drive AI-Powered Energy Management Innovation11.11.2025 03:00:00 EET | Press release
Global technology and IT services provider FPT and E.ON Optimum, the digital solutions arm of E.ON UK, under E.ON Group, announced a new agreement to extend their collaboration in digital energy management. The signing marks the next phase of a partnership established in 2022, reaffirming both corporations’ shared vision of harnessing technology to accelerate innovation and sustainability in the energy sector. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251110039775/en/ FPT and E.ON Optimum leaders at the signing ceremony to extend their partnership in AI-powered energy management. Under this agreement, FPT will continue to support the development and operation of E.ON Optimum’s solution platform, a cloud-based energy management system that gives business energy users timely, flexible data analysis, allowing for better and faster decisions on net-zero energy usage. The next phase focuses on maintaining and enhancing web a
Ant International Open Sources Time-Series Transformer AI Model to Enable More Businesses to Benefit from AI-Powered Forecasting11.11.2025 02:30:00 EET | Press release
Ant International, a leading global digital payment, digitisation, and financial technology provider, has released its proprietary Falcon TST (Time-Series Transformer) AI model, the industry-first Mixture of Experts architecture-based big data model with multiple patch tokenizers, supported by up to 2.5 billion parameters. The model has also achieved state-of-the-art zero-shot results on well-acknowledged long-term forecasting benchmarks, such as absolute mean error rates. Deployed internally at Ant International to manage cashflow and FX exposure on an hourly, daily and weekly basis, Falcon TST has achieved accuracy rates of over 90%, and cut the company’s FX costs by up to 60%. Ant International also collaborated with various industry partners to deploy the model in different use cases, such as in helping businesses mitigate FX cost and volatility, as well as to support airlines in offering more stable, competitive pricing to their customers. With the Airports Council International W
The Empire State Building Holiday Celebrations Include: Radio City Rockettes 100 th Anniversary Exhibits, Visits from Santa, Holiday Décor, Movie Screenings, Pop-ups, Lightings, and More11.11.2025 01:08:00 EET | Press release
The Empire State Building (ESB) today announced its Holiday Celebration plans include: holiday décor, classic movie screenings, local pop-ups, festive tower lightings, and a holiday takeover with the Radio City Rockettes to celebrate the most wonderful time of the year at New York City’s number one attraction. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251110124149/en/ The Empire State Building Holiday Celebrations Include: Radio City Rockettes 100th Anniversary Exhibits, Visits from Santa, Holiday Décor, Movie Screenings, Pop-ups, Lightings, and More “There is no better place to celebrate the holidays in New York City than at the Empire State Building Observatory,” said Dan Rogoski, General Manager at the Empire State Building Observatory. “This year, New Yorkers and visitors will enjoy the best of the holiday season in our iconic venue as we celebrate 100 years of the Radio City Rockettes.” Deck the Halls From the grou
Megaport to Acquire Latitude.sh, Creating an Industry-leading Compute and Network-as-a-Service Platform to Power High-performance Applications and AI Workloads Globally11.11.2025 00:17:00 EET | Press release
Megaport Limited (ASX: MP1), the world’s leading Network-as-a-Service (NaaS) provider, today announced it has entered into an agreement to acquire Latitude.sh, a leading global Compute-as-a-Service company delivering high-performance CPU and GPU infrastructure on demand. Following completion of the acquisition, the combined capabilities will create a global platform that unites Megaport’s private, high-speed connectivity fabric with Latitude.sh’s compute infrastructure, enabling enterprises to rapidly deploy and connect critical workloads across more than 1,000 data centres in 26 countries. “Megaport has long been trusted by the world’s largest enterprises to move workloads seamlessly between data centers and the cloud,” said Michael Reid, CEO of Megaport. “By bringing Latitude.sh into the fold, we’re extending that promise beyond the network, and into high-performance, optimized compute, complementing cloud providers. Together, we will not only serve the massive traditional compute ma
Svante and Södra Launch EU-Based Carbon Capture Pilot to Advance Biogenic CO₂ Utilization10.11.2025 23:49:00 EET | Press release
Svante Technologies Inc. (“Svante”), a global leader in solid sorbent-based carbon capture and removal solutions, is proud to share that Södra, Sweden’s largest forest-owner association, has announced it will test Svante’s carbon capture technology at the Värö industrial site in early 2026 and evaluate opportunities for large-scale capture in the future. This pilot project marks Svante’s first deployment in the EU forestry sector and represents a significant step toward scaling biogenic carbon capture in pulp and paper production. The pilot will evaluate the performance of Svante’s proprietary solid sorbent filters in capturing biogenic CO₂ emissions from Södra’s pulp operations, with the goal of enabling new circular value chains and supporting Sweden’s climate targets. A Strategic Step Toward Circular Bioeconomy Södra’s pulp production generates biogenic CO₂, which is a renewable carbon source with potential applications across food, water purification, chemical manufacturing, and e-
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom